Phage-Based Method for Detecting Biomarkers
Summary
The European Patent Office published patent EP4367233A1 for Aqsens Health Oy's phage-based biomarker detection method. The patent covers detection techniques using phage technology with applications in G01N 33/542, 33/68, and 21/64 classifications. Designated states include all major European jurisdictions including DE, FR, GB, IT, ES, NL, and 23 additional contracting states.
What changed
EPO published patent application EP4367233A1 for Aqsens Health Oy, covering a phage-based method for detecting biomarkers. The invention relates to C12N 15/10 and G01N classifications with applications in diagnostics and life sciences. Four inventors are listed: KULPAKKO, LEHTI, TEIMONEN, and RANNIKKO.
This is a patent publication notice with no compliance obligations. No action is required from regulated entities. Companies developing similar phage-based detection technologies should review for potential freedom-to-operate concerns. Patent applicants and IP professionals may use this publication to monitor competitive intellectual property landscapes.
Source document (simplified)
PHAGE-BASED METHOD FOR DETECTING BIOMARKERS
Publication EP4367233A1 Kind: A1 Mar 25, 2026
Applicants
Aqsens Health Oy
Inventors
KULPAKKO, Janne, LEHTI, Vilhelmiina, TEIMONEN, Timo, RANNIKKO, Antti
IPC Classifications
C12N 15/10 20060101AFI20230113BHEP G01N 33/542 20060101ALI20230113BHEP G01N 21/64 20060101ALI20230113BHEP G01N 33/68 20060101ALI20230113BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Biotech (C12N) publishes new changes.